The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Cytokines induced during chronic hepatitis B virus infection promote a pathway for NK cell–mediated liver damage
Open accessAbstract
Hepatitis B virus (HBV) causes chronic infection in more than 350 million people worldwide. It replicates in hepatocytes but is non-cytopathic; liver damage is thought to be immune mediated. Here, we investigated the role of innate immune responses in mediating liver damage in patients with chronic HBV infection. Longitudinal analysis revealed a temporal correlation between flares of liver inflammation and fluctuations in interleukin (IL)-8, interferon (IFN)-α, and natural killer (NK) cell expression of tumor necrosis factor–related apoptosis-inducing ligand (TRAIL) directly ex vivo. A cross-sectional study confirmed these findings in patients with HBV-related liver inflammation compared with healthy carriers. Activated, TRAIL-expressing NK cells were further enriched in the liver of patients with chronic HBV infection, while their hepatocytes expressed increased levels of a TRAIL death–inducing receptor. IFN-α concentrations found in patients were capable of activating NK cells to induce TRAIL-mediated hepatocyte apoptosis in vitro. The pathogenic potential of this pathway could be further enhanced by the ability of the IFN-α/IL-8 combination to dysregulate the balance of death-inducing and regulatory TRAIL receptors expressed on hepatocytes. We conclude that NK cells may contribute to liver inflammation by TRAIL-mediated death of hepatocytes and demonstrate that this non-antigen–specific mechanism can be switched on by cytokines produced during active HBV infection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The biology of human natural killer-cell subsets
Cooper, M. A., Fehniger, T. A., & Caligiuri, M. A. (2001) · Trends in Immunology · doi:10.1016/s1471-4906(01)02060-9 · Cited by 2,975
Identification and characterization of a new member of the TNF family that induces apoptosis
Wiley, S. R., Schooley, K., Smolak, P. J., Din, W. S., Huang, C.-P., Nicholl, J. K., Sutherland, G. R., Smith, T. D., Rauch, C., Smith, C. A., et al. (1995) · Immunity · doi:10.1016/1074-7613(95)90057-8 · Cited by 2,900
Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo.
Walczak, H., Miller, R. E., Ariail, K., Gliniak, B., Griffith, T. S., Kubin, M., Chin, W., Jones, J., Woodward, A., Le, T., et al. (1999) · Nature Medicine · doi:10.1038/5517 · Cited by 2,497
Safety and antitumor activity of recombinant soluble Apo2 ligand
Ashkenazi, A., Pai, R. C., Fong, S., Leung, S., Lawrence, D. A., Marsters, S. A., Blackie, C., Chang, L., McMurtrey, A. E., Hebert, A., et al. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6926 · Cited by 2,213
Control of TRAIL-Induced Apoptosis by a Family of Signaling and Decoy Receptors
Sheridan, J. P., Marsters, S. A., Pitti, R. M., Gurney, A., Skubatch, M., Baldwin, D., Ramakrishnan, L., Gray, C. L., Baker, K., Wood, W. I., et al. (1997) · Science · doi:10.1126/science.277.5327.818 · Cited by 1,664
Viral Clearance Without Destruction of Infected Cells During Acute HBV Infection
Guidotti, L. G., Rochford, R., Chung, J., Shapiro, M., Purcell, R., & Chisari, F. V. (1999) · Science · doi:10.1126/science.284.5415.825 · Cited by 1,223
Jo, M., Kim, T.-H., Seol, D.-W., Esplen, J. E., Dorko, K., Billiar, T. R., & Strom, S. C. (2000) · Nature Medicine · doi:10.1038/75045 · Cited by 843
Schneider, P., Holler, N., Bodmer, J.-L., Hahne, M., Frei, K., Fontana, A., & Tschopp, J. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.187.8.1205 · Cited by 812
Maini, M. K., Boni, C., Lee, C. K., Larrubia, J. R., Reignat, S., Ogg, G. S., King, A. S., Herberg, J., Gilson, R., Alisa, A., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.191.8.1269 · Cited by 800
Self-citationTakeda, K., Hayakawa, Y., Smyth, M. J., Kayagaki, N., Yamaguchi, N., Kakuta, S., Iwakura, Y., Yagita, H., & Okumura, K. (2001) · Nature Medicine · doi:10.1038/83416 · Cited by 775
Type I Interferons Keep Activated T Cells Alive
Marrack, P., Kappler, J., & Mitchell, T. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.189.3.521 · Cited by 759
Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions
Lawrence, D., Shahrokh, Z., Marsters, S., Achilles, K., Shih, D., Mounho, B., Hillan, K., Totpal, K., DeForge, L., Schow, P., et al. (2001) · Nature Medicine · doi:10.1038/86397 · Cited by 702
Involvement of the CD95 (APO-1/Fas) receptor and ligand in liver damage.
Galle, P. R., Hofmann, W. J., Walczak, H., Schaller, H., Otto, G., Stremmel, W., Krammer, P. H., & Runkel, L. (1995) · The Journal of experimental medicine · doi:10.1084/jem.182.5.1223 · Cited by 692
Radaeva, S., Sun, R., Jaruga, B., Nguyen, V. T., Tian, Z., & Gao, B. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.10.055 · Cited by 610
Nguyen, K. B., Salazar-Mather, T. P., Dalod, M. Y., Van Deusen, J. B., Wei, X.-Q., Liew, F. Y., Caligiuri, M. A., Durbin, J. E., & Biron, C. A. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.8.4279 · Cited by 610
Natural Killer T Cell Activation Inhibits Hepatitis B Virus Replication in Vivo
Kakimi, K., Guidotti, L. G., Koezuka, Y., & Chisari, F. V. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.921 · Cited by 584
Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity
Ichikawa, K., Liu, W., Zhao, L., Wang, Z., Liu, D., Ohtsuka, T., Zhang, H., Mountz, J. D., Koopman, W. J., Kimberly, R. P., et al. (2001) · Nature Medicine · doi:10.1038/91000 · Cited by 543
Campbell, J. J., Qin, S., Unutmaz, D., Soler, D., Murphy, K. E., Hodge, M. R., Wu, L., & Butcher, E. C. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.11.6477 · Cited by 517
Kayagaki, N., Yamaguchi, N., Nakayama, M., Eto, H., Okumura, K., & Yagita, H. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.189.9.1451 · Cited by 479
Mechanisms of class I restricted immunopathology. A transgenic mouse model of fulminant hepatitis.
Ando, K., Moriyama, T., Guidotti, L. G., Wirth, S., Schreiber, R. D., Schlicht, H. J., Huang, S. N., & Chisari, F. V. (1993) · The Journal of experimental medicine · doi:10.1084/jem.178.5.1541 · Cited by 449
Incubation Phase of Acute Hepatitis B in Man: Dynamic of Cellular Immune Mechanisms
Webster, G. J. M., Reignat, S., Maini, M. K., Whalley, S. A., Ogg, G. S., King, A., Brown, D., Amlot, P. L., Williams, R., Vergani, D., et al. (2000) · Hepatology · doi:10.1053/jhep.2000.19324 · Cited by 414
Self-citationResident human hepatitis lymphocytes are phenotypically different from circulating lymphocytes
Norris, S., Collins, C., Doherty, D. G., Smith, F., McEntee, G., Traynor, O., Nolan, N., Hegarty, J., & O'Farrelly, C. (1998) · Journal of Hepatology · doi:10.1016/s0168-8278(98)80206-7 · Cited by 374
Brunetto, M. R., Oliveri, F., Coco, B., Leandro, G., Colombatto, P., Gorin, J. M., & Bonino, F. (2002) · Journal of Hepatology · doi:10.1016/s0168-8278(01)00266-5 · Cited by 331
Self-citationMyers, R. P., Tainturier, M.-H., Ratziu, V., Piton, A., Thibault, V., Imbert‐Bismut, F., Messous, D., Charlotte, F., Martino, V. D., Benhamou, Y., et al. (2003) · Journal of Hepatology · doi:10.1016/s0168-8278(03)00171-5 · Cited by 331
Tay, C. H., & Welsh, R. M. (1997) · Journal of Virology · doi:10.1128/jvi.71.1.267-275.1997 · Cited by 318
Tsai, S. L., Chen, P. J., Lai, M. Y., Yang, P. M., Sung, J. L., Huang, J. H., Hwang, L. H., Chang, T. H., & Chen, D. S. (1992) · Journal of Clinical Investigation · doi:10.1172/jci115590 · Cited by 287
Antiviral response by natural killer cells throughTRAIL gene induction by IFN-α/β
Sato, K., Hida, S., Takayanagi, H., Yokochi, T., Kayagaki, N., Takeda, K., Yagita, H., Okumura, K., Tanaka, N., Taniguchi, T., et al. (2001) · European Journal of Immunology · doi:10.1002/1521-4141(200111)31:11<3138::aid-immu3138>3.0.co;2-b · Cited by 271
Polyak, S. J., Khabar, K. S. A., Rezeiq, M., & Gretch, D. R. (2001) · Journal of Virology · doi:10.1128/jvi.75.13.6209-6211.2001 · Cited by 243
Kakimi, K., Lane, T. E., Wieland, S., Asensio, V. C., Campbell, I. L., Chisari, F. V., & Guidotti, L. G. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.194.12.1755 · Cited by 234
Clancy, L., Mruk, K., Archer, K., Woelfel, M., Mongkolsapaya, J., Screaton, G., Lenardo, M. J., & Chan, F. K.-M. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0507329102 · Cited by 232
Mahé, Y., Mukaida, N., Kuno, K., Akiyama, M., Ikeda, N., Matsushima, K., & Murakami, S. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)92765-1 · Cited by 224
Kashii, Y., Giorda, R., Herberman, R. B., Whiteside, T. L., & Vujanovic, N. L. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.10.5358 · Cited by 220
Herbeuval, J.-P. (2005) · Blood · doi:10.1182/blood-2005-03-1243 · Cited by 211
Interleukin-12 induction of Th1 cytokines is important for viral clearance in chronic hepatitis B.
Rossol, S., Marinos, G., Carucci, P., Singer, M. V., Williams, R., & Naoumov, N. V. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119498 · Cited by 210
Afford, S. C., Randhawa, S., Eliopoulos, A. G., Hubscher, S. G., Young, L. S., & Adams, D. H. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.189.2.441 · Cited by 192
Self-citationIshiyama, K., Ohdan, H., Ohira, M., Mitsuta, H., Arihiro, K., & Asahara, T. (2006) · Hepatology · doi:10.1002/hep.21035 · Cited by 186
The Bile Acid Glycochenodeoxycholate Induces TRAIL-Receptor 2/DR5 Expression and Apoptosis
Higuchi, H., Bronk, S. F., Takikawa, Y., Werneburg, N., Takimoto, R., El-Deiry, W., & Gores, G. J. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m105300200 · Cited by 186
Sato, K., Niessner, A., Kopecky, S. L., Frye, R. L., Goronzy, J. J., & Weyand, C. M. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20051062 · Cited by 176
Critical roles of TRAIL in hepatic cell death and hepatic inflammation
Zheng, S.-J., Wang, P., Tsabary, G., & Chen, Y. H. (2004) · Journal of Clinical Investigation · doi:10.1172/jci19255 · Cited by 173
Salazar‐Mather, T. P., Lewis, C. A., & Biron, C. A. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215376 · Cited by 162
Involvement of TRAIL and its receptors in viral hepatitis
Mundt, B., Kühnel, F., Zender, L., Paul, Y., Tillmann, H. L., Trautwein, C., Manns, M. P., & Kubicka, S. (2002) · The FASEB Journal · doi:10.1096/fj.02-0537fje · Cited by 143
The α Chemokine, Interleukin 8, Inhibits the Antiviral Action of Interferon α
Khabar, K. S. A., Al-Zoghaibi, F., Al‐Ahdal, M. N., Murayama, T., Dhalla, M., Mukaida, N., Taha, M., Al‐Sedairy, S. T., Siddiqui, Y. M., Kessie, G., et al. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.186.7.1077 · Cited by 133
MMPs are required for recruitment of antigen-nonspecific mononuclear cells into the liver by CTLs
Sitia, G., Isogawa, M., Iannacone, M., Campbell, I. L., Chisari, F. V., & Guidotti, L. G. (2004) · Journal of Clinical Investigation · doi:10.1172/jci21087 · Cited by 131
Hepatitis B Virus Sensitizes Hepatocytes to TRAIL-Induced Apoptosis through Bax
Liang, X., Liu, Y., Zhang, Q., Gao, L., Han, L., Ma, C., Zhang, L., Chen, Y. H., & Sun, W. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.1.503 · Cited by 105
Balkow, S., Kersten, A., Tran, T. T. T., Stehlé, T., Grosse, P., Muşeţeanu, C., Utermöhlen, O., Pircher, H., von Weizsäcker, F., Wallich, R., et al. (2001) · Journal of Virology · doi:10.1128/jvi.75.18.8781-8791.2001 · Cited by 90
Löhr, H. F., Weber, W., Schlaak, J., et al. (1995) · Hepatology · doi:10.1002/hep.1840220110 · Cited by 89
Janssen, H. L. A., Higuchi, H., Abdulkarim, A., & Gores, G. J. (2003) · Journal of Hepatology · doi:10.1016/s0168-8278(03)00265-4 · Cited by 84
Reynolds, G. M., Billingham, L. J., Gray, L. J., et al. (2002) · British Journal of Haematology · doi:10.1046/j.1365-2141.2002.03575.x · Cited by 77
Self-citationTian, Z., Shen, X., Feng, H., & Gao, B. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.7.3959 · Cited by 71
Down-Modulation of Responses to Type I IFN Upon T Cell Activation
Dondi, E., Rogge, L., Lutfalla, G., Uzé, G., & Pellegrini, S. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.2.749 · Cited by 69
Virally Infected Hepatocytes Are Resistant to Perforin-Dependent CTL Effector Mechanisms
Kafrouni, M. I., Brown, G., & Thiele, D. L. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.3.1566 · Cited by 68
Sprengers, D., Molen, R. G. V. D., Kusters, J. G., Hansen, B. E., Niesters, H. G. M., Schalm, S. W., & Janssen, H. L. A. (2006) · Journal of Medical Virology · doi:10.1002/jmv.20576 · Cited by 42
Cited by
Functions of natural killer cells
Vivier, E., Tomasello, E., Baratin, M., Walzer, T., & Ugolini, S. (2008) · Nature Immunology · doi:10.1038/ni1582 · Cited by 3,943
Immunology in the liver — from homeostasis to disease
Heymann, F., & Tacke, F. (2016) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2015.200 · Cited by 1,180
Crispe, I. N. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132629 · Cited by 986
Roles for chemokines in liver disease
Marra, F., & Tacke, F. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.06.043 · Cited by 829
Hepatitis B Virus Resistance to Nucleos(t)ide Analogues
Zoulim, F., & Locarnini, S. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.08.063 · Cited by 706
Metadata
- Authors
- Dunn, C., Brunetto, M., Reynolds, G., Christophides, T., Kennedy, P. T., Lampertico, P., Das, A., Lopes, A. R., Borrow, P., Williams, K., Humphreys, E., Afford, S., Adams, D. H., Bertoletti, A., & Maini, M. K.
- Venue
- The Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2007-03-12
- Volume
- 204
- Issue
- 3
- Pages
- 667-680
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- OpenAlex
- W2119954580
- Cited by
- 421
- References
- 53
- FWCI
- 17.38
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.